ST. LOUIS — DuPont Nutrition & Health has entered into a joint development and licensing agreement with Inbiose, a Belgium-based processor of specialty carbohydrates. The agreement gives DuPont the rights to selected fucosylated human milk oligosaccharides (H.M.O.s), including 2’-fucosyllactose.
Human milk oligosaccharides are a group of oligosaccharides found in mother’s milk, with 2’-fucosyllactose being the single most abundant H.M.O. The oligosaccharides have been identified as components of human milk that help shape an infant’s gut microbiome and a balanced immune system development.
“This partnership is part of a new era in ingredients targeted for infant nutrition,” said John Rea, global business unit leader for Probiotics, Cultures, Food Protection and H.M.O.s for DuPont. “With this development, we’re working toward fulfilling our corporate mission to help solve the world’s food challenges by providing innovative ingredients our customers can use to make healthy and nutritious products. Our investment here complements the broad capabilities DuPont has built in probiotics and understanding the human gut microbiome, as well as our technologies already targeting this area.”
The partnership combines Inbiose’s innovative production platform for specialty carbohydrates with DuPont’s capabilities in industrial-scale fermentation, regulatory and health science expertise, as well as global market access.
